Rubicon Research’s subsidiary -- Advagen Holdings Inc. (Advagen) has entered into a definitive agreement with GEn1E Lifesciences Inc. (Gen1E), to acquire Series Prime Preferred Stock in tranches, for a total consideration of up to $3 million. Series Prime Preferred Stock, convertible into around 2.2% of Gen1E’s common stock ownership subject to achievement of all milestones.
Gen1E is a pharmaceutical company with a pipeline of product candidates under development. GEn1E is based in Palo Alto, California, with a laboratory in Mountain View, California, USA.
Rubicon Research is a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of speciality products and drug-device combination products targeting regulated markets and in particular the United States.
